Brain IORT | Xoft | Elekta

Brain IORT

Brain Tumor Treatment with Elekta Xoft IORT | Intraoperative Radiation Therapy

Elekta Xoft Brain IORT may offer better outcomes for patients, with minimal side effects

Worldwide, almost 297,000 cases of brain and nervous system tumors are diagnosed per year.1 Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor, with a median survival of 10-12 months. Treatment for brain tumors typically involves surgical removal, followed by radiation therapy or chemotherapy.2,3

Elekta Xoft Brain IORT is a promising treatment option that may offer better outcomes for patients, with minimal side effects, compared to traditional radiation therapy. For the treatment of certain types of brain tumors, IORT with Elekta Xoft may allow appropriately selected patients to potentially replace weeks of post-operative external beam radiation therapy (EBRT) with a single fraction of radiation.

IORT with Elekta Xoft allows radiation oncologists and surgeons to work together to deliver a full course of radiation treatment in one day, at the time of surgery, while the patient is under anesthesia. Once the tumor has been surgically removed, Elekta Xoft’s miniature x-ray source is inserted inside a flexible balloon-shaped applicator, which is then placed inside the tumor cavity, filled with saline, and used to deliver a single dose of radiation directly to the tumor bed.

Elekta Xoft may not be available in all markets. It is supported by a growing body of evidence for the treatment of early-stage breast cancer, non-melanoma skin cancer (NMSC), gynecological cancers and brain cancers.

GLIOX Patient Information GLIOX Investigator’s Information

Advantages of Elekta Xoft

Elekta Xoft Brain IORT is a groundbreaking procedure that has potential to extend lives and address a significant unmet need in the treatment of several types of cancers including metastatic brain tumors and gioblastoma (GBM).

Brain Iort

The inflatable balloon provides a minimally invasive approach, fast procedure implementation, and an easy workflow

Inflated Balloon

Optimized adherence of the inflated balloon to the resected cavity

Axxent X Ray Source

50 kV System allows a significant sparing of the healthy tissue prone to dose escalation and longer OS and loc PFS in patients with GBM relapse

What our customers say

“We were encouraged by preliminary data supporting Xoft IORT for brain tumors, and we are impressed with the protocol of the GLIOX trial evaluating an innovative therapeutic approach to treat recurrent GBM. When we were offered the opportunity to treat patients with Xoft IORT, as well as the chance to potentially join the GLIOX trial, we immediately began using the new approach on patients with GBM and other tumor types. Although it is still early, results thus far are encouraging. This method offers hope for certain types of disease, as it may allow us to select patients for a treatment that could replace weeks of external beam radiotherapy (EBRT).”

Marta Ortega, MD, NS,
Cáceres University Hospital, Spain

“This is a significant milestone, not just for our institute, but also for patients with recurrent glioblastoma. The initiation of a clinical trial under normal circumstances is no small feat, but the COVID pandemic presented additional challenges that had to be overcome. It truly was an enormous achievement, and we are excited that we can now offer it to patients.”

Naveed Wagle, MD,
Associate Professor of Neurosciences at the Saint John’s Cancer Institute

“Treatment options for patients with recurrent GBM are extremely limited. As such, we are encouraged by the interim results that demonstrate significant improvement in OS and locPFS in recurrent GBM patients with maximal safe resection plus Xoft Brain IORT compared to re-resection followed by various alternative adjuvant therapy options (mostly external beam re-irradiation plus chemotherapy). This innovative approach is equivalent to multiple sessions of external beam radiation therapy (EBRT), yet with minimized risk of radiation dose to neighboring healthy tissues. We encourage collaboration on further multidisciplinary, multicenter clinical trials as the initial data is promising.”

Alexey Gaytan, MD, PhD,
Neurosurgeon at the European Medical Center

“New treatments for recurrent GBM are greatly needed, and local recurrence is often inevitable after the first round of radiation therapy due to resistance to radiation. However, clinical results are beginning to reveal that Xoft Brain IORT shows significant promise for treating recurrent GBM, and we are eager to begin evaluating its feasibility and safety on patients here at the Sarah Cannon Cancer Institute.”

Michael Howard, PhD, DABMP, RSO,
Director of Oncology Services and Chief of Medical Physics, at the Sarah Cannon Cancer Institute at the Parkridge Medical Center, Chattanooga, TN

“GBM is one of the most aggressive cancers with very poor survival and innovative approaches are needed. We are eager to open this international Phase II multi-center study using Xoft IORT as a potential new approach to local control of this devastating disease. In particular, if the results of this Phase II medical device trial confirm previously reported results, this innovative technology could rapidly be adopted since it is previously cleared for use by the FDA for treatment of cancer anywhere in the body.”

Santosh Kesari, MD, PhD,
Director of Neuro-oncology Chair and Professor, Department of Translational Neurosciences at Saint John's Cancer Institute in Santa Monica, CA

“We are encouraged by the promising results we’ve seen using IORT to deliver the required prescribed single focal dose that is equal to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue for the treatment of recurrent GBM. While our findings concluded feasibility, more clinical trials are warranted, and we whole-heartedly applaud the collaborative efforts.”

Alexey Krivoshapkin, MD, PhD,
Neurosurgeon at the European Medical Center (EMC) in Moscow, Russia

"We’ve treated four patients in our trial and our initial experience suggests IORT using the Xoft eBx system for treatment of large, resected brain metastases is well tolerated without unexpected early adverse treatment effects.”

Mehran Yusuf, MD,
Radiation Oncologist at the James Graham Brown Cancer Center at the University of Louisville

Clinical Research

Elekta Xoft is currently being studied for the treatment of multiple types of brain tumors in leading institutions worldwide. Following please find details of ongoing research

Clinical Research
Female Doctorthinking at her laptop

GLIOX Trial Announcement

Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with Xoft Brain IORT Technology to Support Clinical Adoption

GLIOX Investigator’s Information
GLIOX Patient Information

Axxent Products

Discover our Advanced, Multi-Platform System

Customer support

Customer support

Please consult with your Elekta Representative for availability of Xoft.